Home » Stocks » SKYE

Skye Bioscience, Inc. (SKYE)

Stock Price: $0.1095 USD -0.0065 (-5.60%)
Updated Feb 26, 2021 3:58 PM EST - Market closed
Market Cap 27.38M
Revenue (ttm) n/a
Net Income (ttm) -206,540
Shares Out 256.76M
EPS (ttm) -0.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $0.1095
Previous Close $0.1160
Change ($) -0.0065
Change (%) -5.60%
Day's Open 0.1155
Day's Range 0.1000 - 0.1190
Day's Volume 2,980,667
52-Week Range 0.068 - 0.246

News

Hide News
  • All
  • Videos
  • Press Releases
Benzinga - 4 days ago

The following article is sponsored by Skye Bioscience, Inc. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers a...

GlobeNewsWire - 3 weeks ago

San Diego, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic can...

Other stocks mentioned: EMBI
Benzinga - 1 month ago

Skye Bioscience, formally Emerald Bioscience, was one of the sponsors for the Benzinga Global Small Cap Conference that took place on December 8-9, 2020. The information contained in this arti...

GlobeNewsWire - 1 month ago

Name change reflects Company's evolution, renewed team and strategic focus on advancing its lead compound into human trials Company to trade under ticker SKYE effective January 19, 2021 Name c...

Other stocks mentioned: EMBI
GlobeNewsWire - 1 month ago

San Diego, Calif, Jan. 15, 2021 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“EMBI” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic c...

GlobeNewsWire - 1 month ago

San Diego, Calif, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald” or the “Company”), a biopharmaceutical company focused on developing differentiated, propr...

GlobeNewsWire - 2 months ago

Drug Delivery and Translational Research article highlights significantly better drug load and duration of activity of prodrug of THC compared to leading commercial drugs for treating glaucoma

Benzinga - 2 months ago

The rapid innovation and growth in biotechnology is being used to define, validate, and enhance therapeutic outcomes from cannabinoids. The results could prove highly valuable to patients, as ...

GlobeNewsWire - 4 months ago

Renewed team and capital focused on advancing lead compound for glaucoma into human studies

GlobeNewsWire - 5 months ago

San Diego, CA, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI a preclinical-stage biopharmaceutical company focused on the development of proprietary first-in-class...

GlobeNewsWire - 6 months ago

Renewed team and capital focused on advancing lead compound for glaucoma into clinical development Renewed team and capital focused on advancing lead compound for glaucoma into clinical develo...

GlobeNewsWire - 6 months ago

Renewed team and capital focused on advancing lead compound for glaucoma into clinical development

GlobeNewsWire - 6 months ago

Long Beach, CA, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald”), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to a...

GlobeNewsWire - 6 months ago

Long Beach, CA, July 31, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald”), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to ...

GlobeNewsWire - 8 months ago

Bio-engineered analog of CBD (CBDVHS) exhibited highly significant potency when compared to CBD in lowering biomarkers associated with inflammation and fibrosis in a validated human tissue mod...

Seeking Alpha - 1 year ago

GW Pharmaceuticals benefiting from competitors' setbacks.

Other stocks mentioned: EMBI, GWPH
Benzinga - 1 year ago

After reporting some strong results from its studies last month, cannabinoid biopharmaceutical company Emerald Bioscience Inc recently made headlines again.

About SKYE

Skye Bioscience, a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics for unmet medical needs worldwide. The company's lead product candidate is NB1111, which is in preclinical trials for the treatment of glaucoma. It is also developing NB2222, a product candidate in preclinical trials for use in the treatment of various eye diseases, including uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy; and NB3111, a cannabinoid cocktail in testing for use as ... [Read more...]

Industry
Biotechnology
Founded
2012
CEO
Brian Murphy
Employees
4
Stock Exchange
OTCMKTS
Ticker Symbol
SKYE
Full Company Profile

Financial Performance

Financial Statements